放疗联合吉西他滨加顺铂治疗Ⅲ期非小细胞肺癌临床观察

目的观察常规放疗联合吉西他滨（泽菲）加顺铂同步化疗治疗局部晚期非小细胞肺癌（NSCLC）的近期疗效与安全性。方法62例局部晚期NSCLC患者，实施常规放疗，计划照射剂量（60—75）Gy，（2～2．5）Gy／次，1次／d，5d／wk。同步行吉西他滨加顺铂化疗，方案为放疗d1起开始化疗，化疗方案为吉西他滨1．0g/m2，d1，d8，顺铂25mg／m2，d1～3，每21d重复。放疗后再采用该方案化疗共4-6个周期。结果近期疗效CR9例，PR41例，SD7例，PD5例。有效率80．6％。毒副反应主要为恶心、呕吐、骨髓抑制，放射性食管炎，放射性肺炎。结论常规放疗联合吉西他滨加顺铂同步治疗局部晚期NSCLC近期疗效好，毒副反应可耐受，远期疗效有待进一步随访研究。

Clinicall observation on radiotherapy combined with chemootheray in the treatment of 62 cases with local advanced non-small cell lung cancer

Objective To investigate the efficacy and to xicities of radiotherapy combined with Gemeitabine Plus cisplatin as a radiochemotherapy regimen for patients with loal advanced non -small cell lung cancer （NSCLC）. Method 62 cases patients with stage Ⅲ NSCLC were treated with convertional radiotherapy combined with Gemeitabine and eisplatin.the radiotherapy was given in 2-2.5Gy/fraction, 5fraction/w, to a total close of 60-75 Gy. chemotherapy was given from the first day of CRT, with Gemcitabine 1.0g/m2 on dayl to day8, cisplatin 25my/m2 on dayl to day3.the chemothtrapy was repeated every 21 days, with a total of 4-6 cycles. Results Complete response （CR） partial response （PR）, stable disease （SD） and progressive disease （PD） were observed in 9, 41, 7 and 5 cases, respectively, with a response rate （RR） of 80.6%. The main toxicities were tolerable, which in eluded myelosuppression,nausea,vomiting acute radiation pneumonia and acute radiation esophagitis. Conclusion Convertional Radiotherapy （CRT） combined concurrent Gemcitabine and eisplatio is effective and safe in most patients with stage Ⅲ non-small cell lung cancer, long term results await further follow-up.